Literature DB >> 24570907

Chemoprevention for hepatocellular carcinoma: the role of statins.

Giuseppe Cabibbo1, Salvatore Petta1, Calogero Cammà1.   

Abstract

Entities:  

Year:  2013        PMID： 24570907      PMCID： PMC3924640          DOI： 10.3978/j.issn.2304-3881.2012.09.01

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  17 in total

1.  The risk of cancer in users of statins.

Authors:  Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

2.  Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.

Authors:  Yu-Tse Tsan; Chang-Hsing Lee; Jung-Der Wang; Pau-Chung Chen
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

3.  Boceprevir for previously treated chronic HCV genotype 1 infection.

Authors:  Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Patrick Marcellin; John M Vierling; Stefan Zeuzem; Fred Poordad; Zachary D Goodman; Heather L Sings; Navdeep Boparai; Margaret Burroughs; Clifford A Brass; Janice K Albrecht; Rafael Esteban
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

4.  Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

Authors:  Stephen A Harrison; Lorenzo Rossaro; Ke-Qin Hu; Keyur Patel; Hans Tillmann; Sandeep Dhaliwal; Dawn M Torres; Kenneth Koury; Venkata S Goteti; Stephanie Noviello; Clifford A Brass; Janice K Albrecht; John G McHutchison; Mark S Sulkowski
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

5.  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Thomas D Gossios; Theodora Griva; Panagiotis Anagnostis; Konstantinos Kargiotis; Efstathios D Pagourelias; Eleni Theocharidou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Lancet       Date:  2010-11-23       Impact factor: 79.321

6.  Statins and the risk of colorectal cancer.

Authors:  Jenny N Poynter; Stephen B Gruber; Peter D R Higgins; Ronit Almog; Joseph D Bonner; Hedy S Rennert; Marcelo Low; Joel K Greenson; Gad Rennert
Journal:  N Engl J Med       Date:  2005-05-26       Impact factor: 91.245

Review 7.  Primary and secondary prevention in the reduction of cancer morbidity and mortality.

Authors:  H O Adami; N E Day; D Trichopoulos; W C Willett
Journal:  Eur J Cancer       Date:  2001-10       Impact factor: 9.162

Review 8.  Causes of and prevention strategies for hepatocellular carcinoma.

Authors:  Giuseppe Cabibbo; Marcello Maida; Chiara Genco; Michela Antonucci; Calogero Cammà
Journal:  Semin Oncol       Date:  2012-08       Impact factor: 4.929

9.  An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.

Authors:  Hitomi Sezaki; Fumitaka Suzuki; Norio Akuta; Hiromi Yatsuji; Tetsuya Hosaka; Masahiro Kobayashi; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Intervirology       Date:  2009-04-17       Impact factor: 1.763

10.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.